Ascendis Pharma A/S (ASND)

Market Cap	11.53B
Revenue (ttm)	576.33M
Net Income (ttm)	-318.44M
Shares Out	60.55M
EPS (ttm)	-5.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	978,026
Open	185.19
Previous Close	182.60
Day's Range	181.43 - 190.35
52-Week Range	111.09 - 190.35
Beta	0.40
Analysts	Strong Buy
Price Target	222.71 (+17.0%)
Earnings Date	Aug 7, 2025

About ELEV

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 28, 2015
• Employees: 1,017
• Stock Exchange: NASDAQ
• Ticker Symbol: ASND
• Website: https://ascendispharma.com

Financial Performance

In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.

Analyst Summary

According to 17 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $222.71, which is an increase of 17.00% from the latest price.

Price Target

$222.71

(17.00% upside)

Analyst Consensus: Strong Buy